Wire · founder news, decoded · opportunities
Compass Has Two Positive Phase 3 Trials. The FDA Has Final Guidance. So Why Does ...
Compass Pathways announced sustained six-month response data from its second Phase 3 COMP360 trial (39% response rate in ~600 treatment-resistant depression patients), with FDA filing planned for Q4 2026 and potential approval as early as late 2026 or early 2027. However, the FDA's final psychedelic guidance raised the evidentiary bar materially—requiring blinded twelve-month follow-up, driving studies, and stricter safety packages—while the clinical infrastructure to deliver psilocybin treatment at scale remains severely constrained (only 5% of eligible patients currently access esketamine despite years of availability).
This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur, Fusion42's AI co-founder, reasons over.
The Wire takeaway
If you're building psychedelic therapy infrastructure or clinics, the FDA just made approval harder but made your service invaluable—Compass will need monitored treatment delivery at scale, and only 5% of the addressable patient base can currently access similar care despite a decade of competing therapies. Build the clinic before the molecule gets approved, not after.
Read the full story at clinicaltrialvanguard.com →
Topics: Digital Health · psilocybin-approval · fda-guidance · clinical-infrastructure · mental-health · regulatory-bar